You are here » About Galderma » Company History

Company History

Dermatology company Galderma’s detailed timeline:


Nestlé Skin Health creates Consumer Skin Health business. 
Galderma enters neutraceutical market with acquisition of certain Innéov assets. 
Opening of branch office/MEA regional headquarters in Dubai.
Launch of Soolantra cream 1% (rosacea) in the U.S. and Europe. Launch of Epiduo Forte Gel, 0.3%/2.5% in the U.S.
Plant extension in Brazil.


Foundation of Nestlé Skin Health. Galderma is now fully-owned by Nestlé.
Galderma enters into an agreement with Valeant, through which Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.


Acquisition of Swiss company Spirig Pharma AG, manufacturer of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.


Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.
Cetaphil Dermacontrol is launched in 6 countries.


Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Plant extensions in France and Canada.


Galderma hits the 1 billion mark in sales.
Launch of Cetaphil Restoraderm. Launch of Restylane Skincare series with NASHA™
Differin Lotion 0.1% (acne) launch in the United States.


Launch of Vectical (psoriasis), Azzalure (glabellar lines) and Restylane Injector, an innovative type of injection device which simplifies the rejuvenation treatment and wins the prestigious Red Dot Design Award.
Galderma purchases global rights, assets, and liabilities related to Metvix and Aktilite.
Restylane obtains registration approval in China and becomes the first injectable non-animal hyaluronic acid product on the Chinese market.


Launch of Epiduo (acne).
Acquisition of CollaGenex Pharmaceuticals
and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan.


Licensing agreements for abotulinum toxin type A and Pliaglis (topical anesthetic).
Launch of Differin 0.3%.


Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.


Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).


Inauguration of the new research and preclinical development building in Sophia Antipolis, France.
Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.


Launch of Metvix in Germany and the UK and Clobex Lotion (psoriasis) in the US.
Restylane is approved in the US.


Licensing agreements for Tri-Luma (pigmentary disorders) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.


Licensing agreement for Metvix (skin cancer).
Launch of Clindagel (acne).


The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).


Acquisition of Loceryl (fungal nail infections), developed by F. Hoffmann-La Roche Ltd, together with the Scandinavian dermatology portfolio developed by Nycomed.


Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.


Acquisition of Basotherm, a subsidiary of Boehringer.


Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.
Restylane is approved for sales in Europe, for filling out of wrinkles and lip augmentation.


Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.
The NASHA patent is filed.


Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.


Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.
Launch of Daylong by Spirig Pharma.


Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.


Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.


Q-Med is founded by Bengt Ågerup with a view to commercializing the research that he had carried out around hyaluronic acid.


Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.


Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.


L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.


Nestlé acquires Alcon to strengthen its presence in the North American market.


Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
Launch of Excipial by Spirig Pharma. 


Creation of the Owen dermatology company in Dallas, Texas, USA


Creation of Spirig Pharma in Olten (Switzerland).

Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world



We are committed

See all videos